Page last updated: 2024-11-11

ro 48-5033

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 48-5033: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6426755
CHEMBL ID3901721
SCHEMBL ID7205072
MeSH IDM0332079

Synonyms (27)

Synonym
n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-4-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide
4-(2-hydroxy-1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-benzenesulfonamide
FT-0669430
unii-vz7ynj87xh
ro 48-5033
hydroxybosentan
ro 48-8634
benzenesulfonamide, 4-(2-hydroxy-1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-
vz7ynj87xh ,
253688-60-7
hydroxy bosentan
bosentan metabolite ro 48-5033
SCHEMBL7205072
FAJQMBCLPZWTQJ-UHFFFAOYSA-N
n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]4-(2-hydroxy-1,1-dimethylethyl)benzenesulphonamide
n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]-4-(2-hydroxy-1,1-dimethylethyl)benzenesulphonamide
AKOS030239680
J-015960
CHEMBL3901721
FT-0669431
FT-0669432
CS-0081840
HY-121385
BCP15832
hydroxybosentan pound>>ro 48-5033 pound>>ro 48-8634 pound>>bosentan metabolite ro 48-5033
4-(2-hydroxy-1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)benzenesulfonamide
4-(2-hydroxy-1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2?-bipyrimidin]-4-yl]-benzenesulfonamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic profiles of bosentan and its pharmacologically active hydroxy metabolite, Ro 48-5033, were determined after each dose of bosentan."( Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects.
Dingemanse, J; van Giersbergen, PL, 2005
)
0.55

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of bosentan was 43% to 48%, with a small interindividual variability of 20%."( Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Birnboeck, H; Eggers, H; Hopfgartner, G; Jonkman, JH; Meyer, J; Schmitt, R; van Marle, S; Viischer, HW; Weber, C, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1323162Drug level in human liver microsomes treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1323173Retention time of the compound2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1323149Drug level assessed as human recombinant CYP3A4-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1323171Drug level assessed as human recombinant CYP2C9-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]